Vevo 2100 Ultrasound System

描述（由申请人提供）：小鼠研究为正常组织和包括癌症在内的病变组织的发展提供了巨大的见解。对小鼠进行重复和无创成像的能力对于了解治疗干预的过程和尽量减少实验中小鼠的使用是必要的。超声成像是高分辨率成像的公认标准，提供了重复、廉价、研究者操作、实时监测小鼠的能力。许多由美国国立卫生研究院资助的研究人员在加州大学旧金山帕纳萨斯分校使用老鼠，他们依靠的是一台Vevo 770超声小动物成像仪，该成像仪将被转移到位于Mission Bay的新开放的研究园区。这一计划将使研究人员无法进行无创成像。由于小鼠在屏障后面，其他成像方式（如MRI、CT或PET扫描）的纵向研究不可能进行，因为它们位于屏障设施之外。因此，这些研究人员已经加入申请一种新的超声波，在这个过程中，他们决定利用新的Vevo 2100的更高分辨率、更大的景深和血管分析能力。该应用程序的多个主要用户各不相同，但都希望在小鼠中进行纵向、非侵入性研究。高分辨率成像将提高研究人员诊断肿瘤新生发展、定位组织以准确注射、确认早期植入和监测肺发育模型胚胎发育的能力。增加的聚焦深度将使整个腹部器官的可视化，需要检测和监测胰腺肿瘤和间皮瘤。多普勒分量（脉冲波和功率）可以显示组织的脉管系统及其随时间的变化。3D功能将快速准确地测量特定结构（如肿瘤）的体积，并将显示组织的异质性，以便不同区域可以单独分析。最后,

DESCRIPTION (provided by applicant): Mouse studies offer tremendous insight into the development of normal tissues and of diseased tissues including cancer. The ability to image mice repeatedly and non-invasively is necessary for understanding the course of therapeutic interventions and to minimize the use of mice in experimentation. Ultrasound imaging is the accepted standard for high resolution imaging, offering the ability for repeated, inexpensive, investigator-operated, real-time monitoring of mice. The many NIH-funded investigators using mice at the University of California San Francisco Parnassus have relied on a Vevo 770 ultrasound small animal imager that will be moved to the newly opened research campus at Mission Bay. This planned move will leave the investigators without the ability for noninvasive imaging. Because the mice are behind a barrier, longitudinal studies by other imaging modalities such as MRI, CT or PET scanning are not possible due to their locations outside the barrier facility. Thus, these investigators have joined to apply for a new ultrasound and, in the process, have decided to take advantage of the higher resolution, greater depth of field and capabilities for vascular analysis of the new Vevo 2100. The multiple major users on this application are diverse, but are united by the desire to carry out longitudinal, non-invasive studies in mice. The high resolution imaging will enhance the ability of researchers to diagnose tumor development de novo, localize tissues for accurate injection, and confirm early implantation and monitor embryonic development in models of lung development. The increased depth of focus will enable visualization of organs throughout the abdomen, needed for detecting and monitoring pancreatic tumors and mesothelioma. The Doppler components (pulsed wave and power) will permit visualization of the vasculature of a tissue and its change over time. The 3D capability will rapidly and accurately measure the volume of a defined structure, such as a tumor, and will display the heterogeneity of tissues so that different regions can be analyzed separately. Finally, the contrast enhancement features expand the capabilities of the ultrasound: with non-targeted synthetic bubbles, the Vevo 2100 can quantify relative blood flow to an organ; with synthetic bubbles targeted to various endothelial targets such as VEGF receptor, the Vevo 2100 can identify relative expression of the targets characteristic of tumor angiogenesis. A Vevo 2100 Small Animal Imager would immediately address the needs of the NIH- funded investigators included here as major users and would enhance opportunities for all mouse users of the barrier facility. With the added support of the Simmons Mesothelioma Foundation to provide long-term maintenance, this state-of-the-art small animal imager will enhance research for the diverse community of those studying mice at UCSF. Relevance to Public Health: Mouse models of human disease are essential for understanding the underlying biology of disease and for developing effective therapies. The translational value of studies will be greatly enhanced by the ability to image living mice non-invasively and repetitively over time. A small animal ultrasound imaging system will allow investigators to monitor mice used in their research for the development of conditions and the response to therapy, thereby increasing efficiency, reducing the number of mice needed, and speeding the development of potential treatments for patients.